Among GBM patients with TMZ-containing treatment, MGMT methylation benefited to both Caucasian and Asian (Asian OS: HR = 0.48, 95% CI 0.42–0.54, p < 0.001, Bon = 0.017, I2 = 43.8%; PFS: HR = 0.49, 95% CI 0.41–0.59, p < 0.001, Bon = 0.014, I2 = 0%; Caucasian OS: HR = 0.46, 95% CI 0.39–0.55, p < 0.001, Bon = 0.017, I2 = 75.5%; PFS: HR = 0.46, 95% CI 0.34–0.63, p < 0.001, Bon = 0.014, I2 = 76.2%, Figure S6 in Supplementary Material). Here, MGMT is linked to glioblastoma.